Hydra Adds $34 Million

Hydra Biosciences Inc., a Cambridge, Mass.-based developer of drugs that target ion channels, has raised $34 million in Series C funding, according to a regulatory filing. Advanced Technology Ventures led the round, and was joined by return backers Abingworth Management, BioVentures Investors, Lilly Ventures, New Enterprise Associates and Polaris Venture Partners. www.hydrabiosciences.com